Table 3.
Clinical response to FEAM conditioning regimen and patient status at last follow‐up
| Before FEAM | After FEAM | |||||
|---|---|---|---|---|---|---|
| Response | N (%) | Response | N (%) | Clinical status | N (%) | |
| All patients (n = 122) | CR | 57 (47·6) | CR | 101 (82·8) | CR | 87 (71·3) |
| PR | 50 (41) | PR | 9 (7·4) | PR | 5 (4·1) | |
| RD | 15 (12·3) | RD | 9 (7·4) | PD | 12 (9·8) | |
| DT | – | DT | 3 (2·4)a | DT | 18 (14·8) | |
| According to response to upfront chemotherapy | ||||||
| Primary refractory (n = 64) | CR | 21 (32·8) | CR | 47 (73·5) | CR | 39 (60·9) |
| PR | 31 (48·4) | PR | 7 (10·9) | PR | 4 (6·3) | |
| RD | 12 (18·8) | RD | 7 (10·9) | PD | 6 (9·4) | |
| DT | – | DT | 3 (4·7)a | DT | 15 (23·4) | |
| Early relapse (n = 32) | CR | 23 (71·9) | CR | 29 (90·6) | CR | 25 (78·1) |
| PR | 8 (25·0) | PR | 2 (6·3) | PR | 1 (3·1) | |
| RD | 1 (3·1) | RD | 1 (3·1) | PD | 5 (15·7) | |
| DT | – | DT | 0a | DT | 1 (3·1) | |
| Relapse (n = 26) | CR | 13 (5·0) | CR | 25 (96·2) | CR | 23 (88·5) |
| PR | 11 (42·3) | PR | 0 | PR | 0 | |
| RD | 2 (7·7) | RD | 1 (3·8) | PD | 1 (3·8) | |
| DT | – | DT | 0a | DT | 2 (7·7) | |
Primary refractory disease: failure to achieve CR, progression during first line chemotherapy or transient response (CR/PR lasting <3 months); early relapsed disease, CR lasting <12 months; relapsed disease, CR lasting >12 months).
FEAM, fotemustine, etoposide, cytarabine, melphalan; CR, complete response; PR, partial response; RD, resistant disease; PD, progression of disease; DT, death; ASCT, autologous stem cell transplantation.
a
Transplant‐related mortality.